Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS
Tarsus Pharmaceuticals — Q1 2025 Earnings Presentation
14 slides from Tarsus Pharmaceuticals's earnings presentation, May 1, 2025
Slide 1: First Quarter 2025 Financial Results Conference Call
First Quarter 2025 Financial Results Conference Call May 1, 2025 Matt, an XDEMVY® Patient
Slide 2: Today's Speakers
Today’s Speakers Bobby Azamian, MD, PhD Aziz Mottiwala Jeff Farrow CEO & Chairman Chief Commercial Officer Chief Financial & Strategy Officer 2 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. These statements include statements regarding the potential commercial success and growth of XDEMVY in Demodex blepharitis, including market size, acceptance, demand, and adoption r
Slide 4: Tarsus: A Leader in Eye Care
Tarsus A Leader in Eye Care XDEMVY®: Pioneering Next Well Positioned Potential New Category: for Continued Blockbuster Ocular Rosacea Growth 4 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 5: XDEMVY: Next Potential Blockbuster in Eye Care
XDEMVY Next Potential Blockbuster in Eye Care >$78M Net product sales in Q1 2025 ~72K Bottles delivered to patients in Q1 2025 ~9M Patients proactively seeking treatment Just Scratching the Surface on the ECP Prescribing Potential Abby, an XDEMVY patient. ECPs = Eye Care Providers 5 | © Tarsus Pharm
Slide 6: XDEMVY Key Growth Drivers
XDEMVY Key Growth Drivers Optimized Sales Force Changing practice patterns & increasing utilization across >15K ECPs Strong Commercial, Medicare & Medicaid Coverage >90% of total covered lives Action-Oriented Direct-to-Consumer Campaign Patients beginning to ask for XDEMVY by name Ongoing Evidence G
Slide 7: Upcoming Potential Value Driving Catalysts
Upcoming Potential Value Driving Catalysts Greater U.S. Europe Japan China* TP-04 for Ocular Rosacea: XDEMVY for DB: TP-03 for DB: TP-03 for DB: Plans to initiate Ph 2 trial in 2H 2025 On-track for potential regulatory Anticipated to meet with New Drug Application accepted TP-05 for Lyme approval in
Slide 8: Ocular Rosacea: Next Impactful Area of Unmet Need
Ocular Rosacea Next Impactful Area of Unmet Need Targets Root Cause of Disease Demodex mites Sterile Ophthalmic Gel Specifically designed for eyelid & surrounding tissue Pervasive & Damaging Ocular Disease Potential Best-in-Class Molecule • ~15-18M in the U.S.1 Lotilaner • >50% caused by Demodex mit
Slide 9: Well Positioned for Growth
Well Positioned for Growth Proven blueprint for success XDEMVY: One of the fastest growing and best-selling anterior segment medicines Advancing pipeline of category-creating medicines Strong balance sheet continuing to drive growth 9 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 10: XDEMVY: One of the Fastest Growing Anterior Segment Medicines
XDEMVY One of the Fastest Growing & Best-Selling Anterior Segment Medicines 100.0 90.0 $78.3M 80.0 70.0 $66.4M +217% Net Sales ($M) 60.0 YoY growth 50.0 $48.1M $40.8M 40.0 30.0 20.0 $24.7M +18% QoQ growth $13.1M 10.0 $1.7M 0.0 10 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 11: Driving Increased Utilization
Driving Increased Utilization ECP Adoption Coverage Weekly Prescribing Patient Engagement >15K >90% +110% +140% ECPs actively prescribing Commercial, Medicare and Increase in the number of Increase in the average XDEMVY1 Medicaid lives covered2 ECPs prescribing XDEMVY weekly website visits4 weekly3
Slide 12: Strong First Quarter Results
Strong First Quarter Results XDEMVY Net Sales XDEMVY Bottles ($ in millions) Delivered to Patients (in thousands) $78.3 72.0 $66.4 58.5 $48.1 41.4 $40.8 37.0 $24.7 26.0 $13.1 15.0 $1.7 1.7 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 ECPs Prescribing XDEMVY Gro
Slide 13: Second Quarter Outlook
Second Quarter Outlook Prescription Demand GTN Discount ~85-90K ~45-47% XDEMVY bottles expected with improvement expected to be dispensed to patients throughout the year 13 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 14: Q&A
Q&A Bobby Azamian, MD, PhD Aziz Mottiwala Jeff Farrow Sesha Neervannan, PhD CEO & Chairman Chief Commercial Officer Chief Financial & Strategy Officer Chief Operating Officer 14 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Tarsus Pharmaceuticals — Q1 2025 Earnings Presentation on 6ix